Vistagen board amends executive severance plan; severance now payable without Cause outside CIC

Vistagen Therapeutics, Inc.

Board approved an amended and restated Executive Severance Plan on Oct 7, 2026, superseding the Change in Control Executive Severance Plan adopted Aug 11, 2026.
Severance now applies to involuntary terminations without Cause even absent a Change in Control, per the plan effective Oct 7, 2026.
Qualifying Termination window runs from 3 months before to 18 months after a Change in Control; employees need 12 months of full-time service to qualify.
CIC qualifying terminations add full equity acceleration (performance awards at target) and a lump sum of target annual bonus times the Bonus Severance Period.
CEO Shawn K. Singh is deemed an Eligible Employee for Section 6(c) equity acceleration despite his Individual Agreement; all current executive officers are covered.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.